European Society of Hypertension Scientific Newsletter: Hypertension and coronary heart disease

Journal of Hypertension

Volumn 24, Issue 11, 2006, Pages 2323-2325

  Baguet, Jean Philippe ^a   Barone Rochette, Gilles ^a   Mallion, Jean Michel ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VERAPAMIL;

ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; ENDOTHELIAL DYSFUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MICROCIRCULATION; NOTE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 33750256288     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000249719.05006.58     Document Type: Note

References (30)

1. Collins R, McMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50:272-298.
2. Kaplan NM. Multiple risk factors for coronary heart disease in patients with hypertension. J Hypertens 1995; 13 (Suppl 2):S1-S5.
3. McInnes GT. Hypertension and coronary artery disease: cause and effect. J Hypertens 1995; 13 (Suppl 2):S49-S56.
4. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996; 275:1571-1576.
5. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation 1999; 100:354-360.
6. McMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease, part I: effects of prolonged differences in blood pressure. Evidence from nine prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335:765-774.
7. Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, et al. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension 1994; 24:793-801.
8. Collins R, Peto R, McMahon S, Hebert P, Fiebach NH, Eberlein K, et al. Blood pressure, stroke, and coronary heart disease, part II: short-term reductions in blood pressure. Overview of randomised drug trials in their epidemiological context. Lancet 1990; 335:827-838.
9. McMahon S, Rodgers A. The effects of blood pressure reduction in older patients: an overview of five randomised controlled trials in elderly hypertensives. Clin Exp Hypertens 1993; 15:967-978.
10. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322:1561-1566.
11. Lembo G, Morisco C, Lanni F, Barbato E, Vecchione C, Fratta L, et al. Systemic hypertension and coronary artery disease: the link. Am J Cardiol 1998; 82:2H-7H.
12. Schwartzkopff B, Motz W, Frenzel H, Vogt M, Knauer S, Strauer BE. Structural and functional alterations of the intramyocardial coronary arterioles in patients with arterial hypertension. Circulation 1993; 88:993-1003.
13. Antony I, Lerebours G, Nitenberg A. Loss of flow-dependent coronary artery dilation in patients with hypertension. Circulation 1995; 91:1624-1628.
14. Panza JA, Quyyumi AA, Brush JE, Epstein SE. Abnormal endothelium- dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323:22-27.
15. Houghton JL, Frank MJ, Carr AA, von Dohlen TW, Prisant M. Relations among impaired coronary flow reserve, left ventricular hypertrophy and thallium perfusion defects in hypertensive patients without obstructive coronary artery disease. J Am Coll Cardiol 1990; 15:43-51.
16. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
17. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328:914-921.
18. Neaton JD, Grimm RH Jr, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, et al. Treatment of mild hypertension study. Final results. JAMA 1993; 270:713-724.
19. Schmieder RE, Messerli FH. Hypertension and the heart. J Hum Hypertens 2000; 14:597-604.
20. First International Study of Infarct Survival collaborative group. Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986; 2:57-66.
21. The Beta-Blocker Pooling Project research group. The Beta-Blocker Pooling Project (BBPP): subgroup findings from randomized trials in post infarction patients. Eur Heart J 1988; 9:8-16.
22. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA 1988; 260:2088-2093.
23. The SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992; 327:669-677.
24. The Acute Infarction Ramipril Efficacy (AIRE) study investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342:821-828.
25. The Heart Outcomes Prevention Evaluation study investigators. Effects of an angiotensin-converting-enzyme inhibitior, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-153.
26. The European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362:782-788.
27. The Danish Study Group on Verapamil in Myocardial Infarction. Secondary prevention with verapamil after myocardial infarction. Am J Cardiol 1990; 6:33I-40I.
28. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomised controlled trial. JAMA 2003; 290:2805-2816.
29. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
30. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. JAMA 2003; 289:2560-2572.